Searchable abstracts of presentations at key conferences on calcified tissues

Bone Abstracts

Published by BioScientifica
Previous issue | Volume 3 | ECTS2014 | Next issue

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

Card image cap
European Calcified Tissue Society Annual Congress, 17 - 20 May 2014; Prague, Czech Republic

Poster Presentations

Osteoporosis: treatment

Previous section
Osteoporosis: pathophysiology and epidemiology
Table of contents
Next section
Other diseases of bone and mineral metabolism

ba0003pp294 | Osteoporosis: treatment

Targeting the sealing zone, a novel strategy to prevent bone degradation while maintaining bone formation: in vivo proof of concept in three models of pathological bone loss

ba0003pp295 | Osteoporosis: treatment

Bisphosphonate treatment of postmenopausal osteoporosis and circulating levels of DKK1 and sclerostin: effects of treatment regimens

ba0003pp296 | Osteoporosis: treatment

Correlation between 25-OH vitamin D, γδTCR lymphocytes and acute phase reaction after the first zoledronic acid infusion for post-menopausal osteoporosis

ba0003pp297 | Osteoporosis: treatment

Contribution of circulating sclerostin and estradiol for inadequate response to bisphosphonate therapy in women with postmenopausal osteoporosis

ba0003pp298 | Osteoporosis: treatment

Investigating effects of novel conjugate drugs for the treatment of osteoporosis

ba0003pp299 | Osteoporosis: treatment

Association between allopurinol use and hip fracture in older patients discharged from rehabilitation

ba0003pp300 | Osteoporosis: treatment

Resveratrol supplementation increases vBMD at the spine in obese men: a randomized controlled trial

ba0003pp301 | Osteoporosis: treatment

Effect of gastrointestinal events on treatment patterns, discontinuation, resource utilization, and cost in osteoporosis: an analysis using danish health registries

ba0003pp302 | Osteoporosis: treatment

Comparison of osteosarcoma incidence between abaloparatide (BA058) and PTH (1--34) in long term rat studies

ba0003pp303 | Osteoporosis: treatment

Gastrointestinal issues and osteoporosis treatment: the medication use patterns, treatment satisfaction, and inadequate control of osteoporosis study (MUSIC-OS)

ba0003pp304 | Osteoporosis: treatment

Activin decoy receptor (IIA) ameliorates immobilisation induced loss of bone and muscle mass in mice

ba0003pp305 | Osteoporosis: treatment

Treatment with PTH 1--84 influences glucose metabolism trough undercarboxylated osteocalcin

ba0003pp306 | Osteoporosis: treatment

The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study

ba0003pp307 | Osteoporosis: treatment

Effect of daily intake of milk enriched with a high dose of vitamin D in healthy postmenopausal women: preliminary results from a randomized, controlled and double-blind nutritional trial (The EFICALCIO study)

ba0003pp308 | Osteoporosis: treatment

Association of gastrointestinal events and osteoporosis treatment initiation in newly diagnosed osteoporotic Israeli women

ba0003pp309 | Osteoporosis: treatment

Treatment of severe vertebral osteoporosis with teriparatide or 1--84-PTH: results from a Danish Database Initiative

ba0003pp310 | Osteoporosis: treatment

Risk factors for the development of chronic back pain after percutaneous vertebroplasty vs conventional treatment

ba0003pp311 | Osteoporosis: treatment

Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania Region Database

ba0003pp312 | Osteoporosis: treatment

Farnesylpyrophosphate synthase rs2297480 polymorphism and the response to the zoledronic acid in the treatment of postmenopausal osteoporosis

ba0003pp313 | Osteoporosis: treatment

Preclinical evaluation of the link module from human TSG--6 as a novel anti-resorptive agent for postmenopausal osteoporosis

ba0003pp314 | Osteoporosis: treatment

The effect of risedronate on hypogonadal osteoporotic HIV males treated with highly active anti-retroviral therapy: a pilot study

ba0003pp315 | Osteoporosis: treatment

Combination therapy with ibandronate and eldecalcitol enhances bone strength without severe suppression of bone formation in aged ovariectomized rats

ba0003pp316 | Osteoporosis: treatment

Odanacatib treatment improves lumbar vertebral bone mineral density and strength in orchiectomized rabbits

ba0003pp317 | Osteoporosis: treatment

Eldecalcitol improves endothelial function in the femoral artery and prevents bone loss in ovariectomized rats

ba0003pp318 | Osteoporosis: treatment

Preferences of patients and health care professionals for osteoporosis drug treatment: a discrete choice experiment

ba0003pp319 | Osteoporosis: treatment

Perceived vs objective knowledge in patients with osteoporosis

ba0003pp320 | Osteoporosis: treatment

Effects of preventive long-term treatment with strontium ranelate and zoledronic acid to ovariectomized rats on bone microstructure

ba0003pp321 | Osteoporosis: treatment

On-treatment safety and efficacy and short-term efficacy of 1--34 parathyroid hormone treatment in severe osteoporosis

ba0003pp322 | Osteoporosis: treatment

Non attendance at a Bone Health Clinic following hip fracture

ba0003pp323 | Osteoporosis: treatment

To decline screening for osteoporosis: a study on individual decision making, meaning and reasons for non-participation

ba0003pp324 | Osteoporosis: treatment

The effects of risk factors on raloxifene, alendronate, and vitamin D treatment in postmenopausal osteoporosis

ba0003pp325 | Osteoporosis: treatment

Effect of implant to radiologic result in treating osteoporotic intertrochanteric fracture

ba0003pp326 | Osteoporosis: treatment

Undertreatment of osteoporosis: the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC-OS)

ba0003pp327 | Osteoporosis: treatment

Baseline data of the DEVIDE-study: DEnosumab vs Intravenous Ibandronate: a 2-year retrospective head to head real life study

ba0003pp328 | Osteoporosis: treatment

Effects of a preventive long duration treatment of ovariectomized rats with strontium ranelate and zoledronic acid on bone mineral density and bone remodeling

ba0003pp329 | Osteoporosis: treatment

Analysis of adequacy in prescribing calcium supplements based on the daily dairy intake in patients at risk of osteoporosis

ba0003pp330 | Osteoporosis: treatment

Determinants of bone turnover marker response to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

ba0003pp331 | Osteoporosis: treatment

Prevalence of osteoporosis treatment depending on the risk evaluation of the osteoporotic fractures in patients with rheumatoid arthritis in Russia

ba0003pp332 | Osteoporosis: treatment

Denosumab therapy of osteoporosis in patients after solid organ transplantation and impaired renal function

ba0003pp333 | Osteoporosis: treatment

Patients with atypical femoral fractures: characteristics, anabolic treatment and long term follow-up

ba0003pp334 | Osteoporosis: treatment

Comparison of efficacy teriparatide between denosumab and on hip BMD in women with severe post-menopausal osteoporosis

ba0003pp335 | Osteoporosis: treatment

A survey of oral health attitudes and practices amongst bisphosphonate users in UK

ba0003pp336 | Osteoporosis: treatment

The effect of alendronate oral jelly in the treatment of osteoporosis in clinical settings

ba0003pp337 | Osteoporosis: treatment

Monitoring of calcium intake and vitamin D saturation in Slovak postmenopausal women

ba0003pp338 | Osteoporosis: treatment

Patients at high risk of fragility fracture and teriparatide: report from a third level osteoporosis clinic

ba0003pp339 | Osteoporosis: treatment

Recommendations for osteoporosis management and fracture prevention for the frail elderly in long-term care

ba0003pp340 | Osteoporosis: treatment

A clinical case of pregnancy, delivery and lactation in a patient treated with ibandronic acid 3.0 intravenously

ba0003pp341 | Osteoporosis: treatment

Changes on bone turnover markers and bone mineral density in women with postmenopausical osteoporosis treated with denosumab

ba0003pp342 | Osteoporosis: treatment

Assessment treatment with denosumab in clinical practice

ba0003pp343 | Osteoporosis: treatment

Clinical experience with Denosumab in the treatment of osteoporosis

ba0003pp344 | Osteoporosis: treatment

Appropriateness of osteoporosis treatment within a medical in-patient population in a welsh district general hospital

ba0003pp345 | Osteoporosis: treatment

Standardized diagnostic and therapeutic pathway for management of patients with skeletal fragility fractures in the Orthopedic and Physiatrist Unit in an Italian hospital: impact on patient outcome

ba0003pp346 | Osteoporosis: treatment

Efficacy of Denosumab on bone metabolism after a 12-month treatment, in women with severe post-menopausal osteoporosis

ba0003pp347 | Osteoporosis: treatment

The efficacy of the treatment with intravenous ibandronate in common population.

ba0003pp348 | Osteoporosis: treatment

Physical performance and risk of fall in elderly people with severe osteoporosis

ba0003pp349 | Osteoporosis: treatment

Bisphosphonate-associated atypical femoral fracture, effect of teriparatide

ba0003pp350 | Osteoporosis: treatment

Bilateral transient osteoporosis of hip: a case report

ba0003pp351 | Osteoporosis: treatment

A transdermal patch delivering the PTHrP1–34 analog, abaloparatide (BA058), dose-dependently increases spine and hip bmd compared to placebo

ba0003pp352 | Osteoporosis: treatment

Abaloparatide (BA058), a novel human PTHrP analog, restores bone mass and strength in the aged osteopenic ovariectomized cynomolgus monkey

ba0003pp353 | Osteoporosis: treatment

PTH treatment induces WNT10b expression in humans lymphoid cells

ba0003pp354 | Osteoporosis: treatment

Denosumab treatment in women with osteoporosis reduces hip cortical porosity

ba0003pp355 | Osteoporosis: treatment

Continuous modelling-based bone formation could explain sustained increases in hip bone mineral density with denosumab treatment

ba0003pp356 | Osteoporosis: treatment

Changes in lumbar spine QCT, DXA and TBS with denosumab, alendronate or placebo in postmenopausal women with low bone mass

ba0003pp357 | Osteoporosis: treatment

In postmenopausal women previously treated with an oral bisphosphonate and at higher risk of fracture, denosumab significantly increases bone mineral density compared with ibandronate and risedronate

ba0003pp358 | Osteoporosis: treatment

Zoledronate reverses bone marrow adiposity in disuse osteopenic rats

ba0003pp359 | Osteoporosis: treatment

Ten year alendronate use does not adversely affect bone quality compared to 5 years use: a human iliac crest biopsy study

ba0003pp360 | Osteoporosis: treatment

Predictors of second fracture while on treatment with oral bisphosphonates: a multinational retrospective cohort study

ba0003pp361 | Osteoporosis: treatment

Protein malnutrition attenuates bone anabolic response to PTH in female rats

Published by BioScientifica

Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more